Marketing Suicide by Misapplying Population Trends_No Competing Interests?
Suicide rates fluctuate. Like the stock market their rise and fall is not due to a single decisive cause, but rather to a confluence of complex factors.
Suicide rates fluctuate. Like the stock market their rise and fall is not due to a single decisive cause, but rather to a confluence of complex factors.
Industry’s blockbuster sellers–the atypical antipsychotics performed WORSE than their cheaper, non-patented precursors.
Every federal oversight agency evaluating FDA’s safety performance has given the agency flunking grades. See:https://ahrp.org/cms/content/view/148/55/
The harm done by journals’ failure to protect the integrity of science can hardly be overstated.
The law firm of Baum Hedlund filed a lawsuit against GlaxoSmithKline, the maker of the antidepressant, Paxil, for causing severe heart defects in the newborn son, of a woman prescribed Paxil during her pregnancy.
Today’s New York Times editorial hits the mark–it’s right on target!
The Associated Press reports (1, 2 below) that the FDA has just issued new warnings about two additional life-threatening risks induced by SSRI antidepressants: Serotonin Syndrome and Persistent Pulmonary Hypertension in newborn babies.
Following on the heels of an investigative report by David Armstrong of The Wall Street Journal <https://ahrp.org/cms/content/view/286/27/> the Associated Press reports that JAMA claims it was misled.
Three essays provide an overview of the bias that has debased the integrity of medical research literature while increasing the hazards of medical practice–for patients and doctors who are kept in the dark about prescribed treatment dangers.
Two probing first rate investigative reports document how psychiatry’s treatments are shaped by "opinion leaders" whose professional recommendations are compromised by their substantial, largely undisclosed, financial ties to drug companies.
Dr. David Healy, a formidable critic of the iron grip pharmaceutical corporations wield on the practice of psychiatry as well as on psychiatry’s deficient journal reports, directs his criticism at drug regulators in an article in the current British Medical Journal (BMJ).
For almost two decades Eli Lilly has denied that evidence exists demonstrating that its antidepressant Prozac induced violence and suicidality.